Alternate Text DC Chemicals' products qualify for U.S. tariff exemptions. We guarantee no price increases due to customs duties and maintain stable supply, continuing to deliver reliable research solutions to our American clients.

9-ING-41

  Cat. No.:  DC11827   Featured
Chemical Structure
1034895-42-5
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
9-ING-41 is a potent glycogen synthase kinase-3 (GSK-3) inhibitor[1]. 9-ING-41 induces apoptosis and cell cycle arrest at prophase by targeting centrosomes and microtubule-bound GSK-3β. 9-ING-41 has anticancer activity[2].
Cas No.: 1034895-42-5
Chemical Name: 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-1H-pyrrole-2,5-dione
Synonyms: 9ING41;9-ING 41
SMILES: N1C(=O)C(C2=COC3C2=CC(=CC=3)F)=C(C2=CN(C)C3C=C4C(=CC2=3)OCO4)C1=O
Formula: C22H13FN2O5
M.Wt: 404.34
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication: [1]. Ugolkov AV, et al. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs. 2018 Sep;29(8):717-724. [2]. Wu X, et al. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. B
Description: 9-ING-41 is a potent glycogen synthase kinase-3 (GSK-3) inhibitor[1]. 9-ING-41 induces apoptosis and cell cycle arrest at prophase by targeting centrosomes and microtubule-bound GSK-3β. 9-ING-41 has anticancer activity[2].
In Vivo: 9-ING-41 (40 mg/kg/every other day; for 17 days) has single-agent antitumor activity in a mouse model of MCL[2]. Animal Model: NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) mice[2] Dosage: 40 mg/kg Administration: Every other day; for 17 days Result: Had single-agent antitumor activity in a mouse model of MCL.
In Vitro: 9-ING-41 (2, 4 μM; 48 hours) decreases neuroblastoma cell viability induces apoptosis[2]. 9-ING-41 (1, 2 μM; 24 hours) is a potent cell cycle-blocking agent for lymphoma cells[2]. 9-ING-41 (0.1-1 µM) inhibits GSK-3 leading to a decreased expression of the NF-κB target XIAP and significant apoptosis in neuroblastoma cells as shown by PARP cleavage, an apoptosis marker[1]. 9-ING-41 (0.5, 1.0, 1.5, 2.0 μM) inhibits the proliferation rate of all TCL and MCL lines with concentrations as low as 1.0 mM[2]. Cell Viability Assay[2] Cell Line: TCL and MCL lines Concentration: 2, 4 μM Incubation Time: 48 hours Result: Induced apoptosis. Cell Cycle Analysis[2] Cell Line: Lymphoma cells (Jeko, Mino, and OCI-Ly cell lines) Concentration: 1, 2 μM Incubation Time: 24 hours Result: Led to cell cycle arrest in G2/M. Western Blot Analysis[1] Cell Line: SK-N-DZ and SK-N-BE neuroblastoma cells Concentration: 0.1, 1 µM Incubation Time: 48 hours Result: Inhibited GSK-3 leading to a decreased expression of the NF-κB target XIAP.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
Cat. No. Product name Field of application
DC40570 KY19382 KY19382 is a potent and orally active dual inhibitor of CXXC5-DVL and GSK3β, with IC50s of 19 and 10 nM, respectively. KY19382 activates Wnt/β-catenin signaling through inhibitory effects on both CXXC5-DVL interaction and GSK3β activity. KY19382 can be us
DC2067 TDZD-8 TDZD-8 is a non-ATP competitive GSK-3β inhibitor with IC50 of 2 μM.
DC11299 ABC 1183 ABC1183 is a potent, selective, orally active GSK3α/β and CDK9 inhibitor with IC50 of 327/657 nM and 321 nM (CDK9/cyclin T1), shows growth inhibitory activity against a broad panel of cancer cell lines; decreases cell survival through G2/M arrest and modu
DC11827 9-ING-41 9-ING-41 is a potent glycogen synthase kinase-3 (GSK-3) inhibitor[1]. 9-ING-41 induces apoptosis and cell cycle arrest at prophase by targeting centrosomes and microtubule-bound GSK-3β. 9-ING-41 has anticancer activity[2].
DC5144 1-Azakenpaullone 1-Azakenpaullone is a potent and ATP-competitive GSK-3β (glycogen synthase kinase-3β) inhibitor (IC₅₀ = 18 nM).
X